# Neglected Tropical Diseases Diagnosis Market

> Neglected Tropical Diseases Diagnosis Market Research Report By Diagnostic Method (Serological Testing, Molecular Diagnostics, Microscopy, Immunological Assays), By Disease Type (Lymphatic Filariasis, Schistosomiasis, Leprosy, Chagas Disease, Dengue), By End User (Hospitals, Diagnostic Laboratories, Research Institutions, Public Health Organizations), By Technology (PCR Technology, Rapid Test Kits, Next-Gen Sequencing, Automated Analyzers) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.09%
- **2024:** $ 8.75 Billion
- **2025:** $ 9.2 Billion
- **2035:** $ 15.11 Billion
- **Key Players:** Roche (CH), Abbott(US), Siemens Healthineers (DE), Thermo Fisher Scientific (US), BD (US), Cepheid (US), Hologic (US), Bio-Rad Laboratories (US)

**Report ID:** MRFR/HC/32183-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/neglected-tropical-diseases-diagnosis-market-34022

---

## Market Summary

## **Neglected Tropical Diseases Diagnosis Market Overview**

As per MRFR analysis, the Neglected Tropical Diseases Diagnosis Market Size was estimated at 8.75 (USD Billion) in 2024. The Neglected Tropical Diseases Diagnosis Market Industry is expected to grow from 9.20 (USD Billion) in 2025 to 14.38 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.09% during the forecast period (2025 - 2034).

### **Key Neglected Tropical Diseases Diagnosis Market Trends Highlighted**

The Neglected Tropical Diseases Diagnosis Market is experiencing significant growth driven by increasing awareness and initiatives aimed at addressing these diseases. Key market drivers include rising government funding, advancements in diagnostic technologies, and collaborations between public and private sectors focused on enhancing healthcare access in endemic regions. The demand for efficient and rapid diagnostic solutions is on the rise, fueled by the urgent need to control and eliminate neglected tropical diseases that affect vulnerable populations. Emerging opportunities in the market include the development of innovative diagnostic tools tailored for specific diseases and expanding point-of-care testing capabilities.

There is a growing emphasis on integrated diagnostic approaches that combine multiple tests into a single framework, allowing for quicker and more accurate disease detection. This is crucial for timely treatment and better management of patient care. The integration of artificial intelligence and machine learning in diagnostics also holds potential, as these technologies can improve the accuracy and efficiency of existing methods. Recent trends indicate a shift towards more decentralized testing methodologies, enabling diagnosis closer to patients and reducing the need for centralized lab facilities.

Mobile health technology is becoming increasingly popular, facilitating field testing and improving data collection in real-time.

The push for increased accessibility to healthcare services in remote areas propels these changes. As public health organizations continue to prioritize neglected tropical diseases, the market is poised for continued innovation, expanding its reach and effectiveness in combating these conditions globally. Investing in research and development and leveraging the latest technologies will be crucial for stakeholders aiming to capitalize on the evolving landscape of the Neglected Tropical Diseases Diagnosis Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Neglected Tropical Diseases Diagnosis Market Drivers**

### Rising Prevalence of Neglected Tropical Diseases

The increasing prevalence of neglected tropical diseases (NTDs) is a significant driver for the Neglected Tropical Diseases Diagnosis Market Industry. Various factors contribute to the growing incidence of these diseases, particularly in impoverished regions where healthcare infrastructure is often lacking. For instance, poor living conditions, inadequate sanitation, and limited access to clean water make populations more susceptible to infections.As the burden of NTDs continues to rise, so too does the demand for effective diagnostic solutions to identify and manage these diseases. The World Health Organization has highlighted the global health significance of NTDs, which afflicts millions, primarily in developing countries.

With the global market expected to grow at a steady pace, there is a burgeoning need for innovative diagnostic technologies that can enhance disease detection and treatment.

Furthermore, advocacy and awareness campaigns are increasingly focusing on the importance of recognizing and addressing NTDs, which has drawn attention from governments and NGOs. This is pushing for more funding and support for research and development in diagnostic tools, augmenting the growth prospects for the Neglected Tropical Diseases Diagnosis Market. In turn, the development of partnerships between stakeholders is fostering a collaborative environment that seeks to improve diagnostic measures.This scenario involves investment in new technologies and methodologies, further emphasizing the importance of diagnostics in mitigating the impact of NTDs on public health.

The ongoing global initiatives aimed at controlling and eliminating NTDs will inherently demand robust diagnostic capabilities, reinforcing the market's trajectory toward enhancements in diagnostic products and services.

### Technological Advancements in Diagnostic Tools

Technological advancements play a crucial role in propelling the Neglected Tropical Diseases Diagnosis Market Industry forward. The continuous evolution of diagnostic technologies, such as rapid diagnostic tests (RDTs) and molecular diagnostics, has significantly improved the speed and accuracy with which NTDs can be identified. New technologies increase the accessibility and reliability of diagnostic tests, making it easier for healthcare providers to diagnose and manage NTDs, particularly in remote and underserved regions.Furthermore, the integration of point-of-care tests is enabling healthcare professionals to administer tests and obtain results within minutes, which is critical in managing disease outbreaks effectively.

As these technologies advance, they translate into better patient outcomes, paving the way for a more proactive approach to public health.

### Increased Government and NGO Initiatives

The rise in government and non-governmental organizations (NGOs) initiatives focused on combating neglected tropical diseases is a vital market driver. Programs designed to improve healthcare infrastructure, increase awareness, and promote research for NTDs highlight the global commitment to addressing these issues effectively. These initiatives often lead to increased funding for diagnostic solutions, which enables the development and dissemination of innovations tailored for NTD detection.Collaborative efforts between governments, NGOs, and the private sector to enhance diagnostic capabilities drive growth in the Neglected Tropical Diseases Diagnosis Market Industry.

## **Neglected Tropical Diseases Diagnosis Market Segment Insights**

### **Neglected Tropical Diseases Diagnosis Market Diagnostic Method Insights  **

The Diagnostic Method segment within the Neglected Tropical Diseases Diagnosis Market represents a critical facet of the overall industry, contributing significantly to the overall market revenue. By 2023, this segment was valued at 7.93 USD Billion, exhibiting strong growth potential through 2032 with emerging methodologies shaping diagnostics.

Within this realm, 'Serological Testing' holds a major place, valued at 1.7 USD Billion in 2023 and anticipated to grow to 2.8 USD Billion by 2032, showcasing its importance in identifying antibody responses and aiding in the diagnosis of various neglected tropical diseases. This segment not only provides essential diagnosis but also informs treatment decisions, illustrating its vital role in public health.

'Molecular Diagnostics' is a significant contributor in this landscape, valued at 2.15 USD Billion in 2023 and expected to increase to 3.3 USD Billion by 2032. This technique allows for the precise detection of pathogens through DNA/RNA analysis, making it indispensable for rapid and accurate diagnosis, ultimately driving timely interventions. The rise in the prevalence of neglected tropical diseases amplifies the demand for such advanced diagnostic methods, aligning with global health initiatives.

In contrast, 'Microscopy' holds a lesser value at 1.05 USD Billion in 2023, which is projected to reach 1.8 USD Billion in 2032. While it is a traditional method that plays a crucial role in detecting certain pathogens, its growth is slower compared to other diagnostic methods, primarily due to the increasing reliance on molecular techniques that offer rapid and accurate results over manual microscopy. Despite its slower growth, it remains significant where immediate confirmation is necessary.

'Immunological Assays' stands as the largest component within this segment, valued at 3.03 USD Billion in 2023 and expected to grow to 4.5 USD Billion by 2032. These assays are crucial for diagnosing neglected tropical diseases and provide substantial insights into the immunological context of these diseases. Their large market share reflects their widespread use in clinical settings, indicating their effectiveness in disease monitoring and epidemiological studies. As such, these diagnostic methodologies play a decisive role in managing neglected tropical diseases, making them a key focus area for future research and development in the Neglected Tropical Diseases Diagnosis Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Neglected Tropical Diseases Diagnosis Market Disease Type Insights  **

The Neglected Tropical Diseases Diagnosis Market, valued at 7.93 billion USD in 2023, encompasses a diverse range of disease types, each presenting unique challenges and opportunities. Among these, Lymphatic Filariasis remains a critical concern due to its debilitating effects on affected populations, significantly impacting quality of life and contributing to stigma. Schistosomiasis also plays a major role, affecting millions and requiring efficient diagnostic tools to monitor and treat infections effectively. Leprosy's long history and complex treatment pathways continue to necessitate focused diagnosis efforts, highlighting the ongoing need for advancements in this area.

Chagas Disease, prevalent in certain regions, draws attention due to its asymptomatic nature in its initial stages, emphasizing the importance of early detection strategies. Dengue, particularly associated with vector-borne transmission, has become increasingly relevant in global health discussions, further driving demand for reliable diagnostic solutions. This segmentation showcases the multifaceted landscape of the Neglected Tropical Diseases Diagnosis Market, underlining the importance of ongoing innovations and investments to address these diseases effectively.The market growth is supported by evolving healthcare infrastructure and increasing awareness, which play crucial roles in bolstering diagnostic capabilities across these conditions.

### **Neglected Tropical Diseases Diagnosis Market End User Insights  **

The Neglected Tropical Diseases Diagnosis Market is projected to reach a valuation of 7.93 billion USD in 2023, reflecting the critical role played by various end users in addressing neglected diseases. Hospitals and diagnostic laboratories are central to delivering timely diagnoses, hence contributing significantly to the market dynamics. Research institutions play a crucial role in driving innovation and developing new diagnostic technologies, which aligns with the growing focus on improving healthcare outcomes. Public health organizations are vital in implementing widespread screening programs that enhance disease detection and treatment.

This diversified landscape indicates a well-rounded approach to tackling neglected tropical diseases, as collaboration among these end users fosters effective strategies and resource utilization. The overall market is driven by increasing awareness and initiatives aimed at tackling these diseases, with each end-user segment contributing uniquely to the market growth.

The evolving focus on improving diagnostics across all these sectors is set to enhance Neglected Tropical Diseases Diagnosis Market revenue further, providing opportunities for growth and development in the industry.Through enhanced collaboration and technological advancements, the efficacy of disease management is expected to improve significantly, reflecting broader public health needs and priorities.

### **Neglected Tropical Diseases Diagnosis Market Technology Insights  **

The Neglected Tropical Diseases Diagnosis Market, particularly in the Technology segment, is poised for notable growth driven by advancements in diagnostic techniques. As of 2023, the market was estimated to be valued at 7.93 billion USD, reflecting a growing emphasis on innovative solutions. Key technologies within this domain include PCR Technology, which offers rapid and accurate detection, enhancing disease management efforts. Rapid Test Kits are also significant as they provide quick results in resource-limited settings, facilitating timely intervention.Next-gen sequencing is gaining traction due to its high throughput and precision, enabling a comprehensive understanding of pathogens.

Furthermore, Automated Analyzers are becoming essential for increasing efficiency and accuracy in laboratories. The continuous development of these technologies is vital for improving

Neglected Tropical Diseases Diagnosis Market revenue and effectively addressing the challenges posed by neglected tropical diseases. The combination of these technological advancements is crucial, as they collectively address the pressing need for effective diagnosis and treatment, thus fueling overall market growth.

### **Neglected Tropical Diseases Diagnosis Market Regional Insights  **

The Neglected Tropical Diseases Diagnosis Market revenue showcases a diverse composition when examined through the regional lens. In 2023, North America leads the market with a valuation of 2.15 USD Billion, projected to grow to 3.25 USD Billion by 2032, highlighting its majority holding position. Europe follows closely with a value of 1.95 USD Billion in 2023, expected to reach 2.8 USD Billion, emphasizing its significant role in diagnosis development. The APAC region, valued at 2.25 USD Billion in 2023 and anticipated to grow to 3.5 USD Billion, reflects increasing healthcare initiatives supporting disease diagnosis.

Conversely, South America and MEA are smaller players, with market values at 0.9 USD Billion and 0.68 USD Billion in 2023, potentially growing to 1.3 USD Billion and 1.35 USD Billion, respectively. This regional segmentation indicates that while North America and Europe dominate, emerging markets like APAC present substantial opportunities for growth due to increasing investment in healthcare infrastructure and awareness of neglected tropical diseases. Market trends suggest a shift toward enhancing diagnostic capabilities fueled by collaborations and technological advancements across these regions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Neglected Tropical Diseases Diagnosis Market Key Players and Competitive Insights**

The Neglected Tropical Diseases Diagnosis Market is characterized by a diverse range of companies striving to develop innovative diagnostic solutions for various neglected tropical diseases that affect millions in low- and middle-income countries. These diseases, which include but are not limited to schistosomiasis, lymphatic filariasis, and leprosy, have often been overlooked in terms of research funding and market investment. Competition in this market is fueled by a pressing need for affordable, reliable, and user-friendly diagnostic tests that can be deployed in resource-limited settings.

As stakeholders continue to shift focus towards enhancing healthcare access for underserved populations, the market is likely to witness an influx of new entrants, strategic partnerships, and technological advancements aimed at improving diagnosis accuracy and speed. Furthermore, regulatory considerations and the availability of funding opportunities from global health organizations play a crucial role in shaping the competitive landscape of this market.

Siemens Healthineers holds a significant presence in the Neglected Tropical Diseases Diagnosis Market, leveraging extensive expertise in diagnostics and imaging technologies. The company's strength lies in its commitment to research and development, allowing it to introduce innovative products tailored to the needs of healthcare providers addressing neglected tropical diseases. Siemens Healthineers' advanced diagnostic platforms are known for their high sensitivity and specificity, which are essential in accurately identifying various pathogens associated with these diseases. Furthermore, the company's established relationships with healthcare institutions and government organizations enhance its competitive edge, fostering collaboration in developing and deploying diagnostic solutions.

This strategic positioning enables Siemens Healthineers to not only respond to market demands but also to influence public health initiatives aimed at combating neglected tropical diseases globally.

Merck plays a pivotal role in the Neglected Tropical Diseases Diagnosis Market through its focus on delivering high-quality diagnostic tools and solutions that contribute to the early detection and management of these diseases. The company's robust portfolio includes a range of diagnostics designed for use in both laboratory and field settings, making them suitable for implementation in low-resource environments. Merck's commitment to innovation is demonstrated through its continuous investment in new technologies and partnerships with research institutions, which enhance its capabilities in developing effective diagnostic solutions.

The company's strengths include a strong brand reputation and a comprehensive understanding of disease epidemiology, which enable it to provide targeted products that align with public health priorities. This strategic emphasis not only positions Merck as a key player in the market but also supports broader efforts to improve health outcomes in regions affected by neglected tropical diseases.

### **Key Companies in the Neglected Tropical Diseases Diagnosis Market Include**

## **Neglected Tropical Diseases Diagnosis Market Industry Developments**

Recent developments in the Neglected Tropical Diseases Diagnosis Market have drawn significant attention, particularly concerning advancements in diagnostic technologies and innovative partnerships. Companies like Siemens Healthineers and Thermo Fisher Scientific have implemented novel diagnostic solutions that enhance the detection of neglected tropical diseases (NTDs). Merck has been focusing on research collaborations aimed at accelerating the development of diagnostic tools for diseases such as schistosomiasis and lymphatic filariasis.

Notably, Becton Dickinson has seen increased demand for NTD diagnostic kits, contributing to a notable growth in its market valuation, reflecting the rising global awareness of these diseases. On the merger and acquisition front, significant movements have been observed, including Roche's acquisition of a biotech company specializing in infectious diseases, which aims to strengthen its portfolio in the NTD diagnostics sector. Additionally, Abbott and Cepheid are reported to be expanding their product lines to include rapid tests for various NTDs, which could reshape market dynamics.

The combined efforts of these companies are contributing to the overall growth and improving response strategies to combat neglected tropical diseases effectively.

## **Neglected Tropical Diseases Diagnosis Market Segmentation Insights**

**Neglected Tropical Diseases Diagnosis Market Diagnostic Method Outlook**

- [Serological Testing](../../../reports/serological-testing-market-43470)
- Molecular Diagnostics
- Microscopy
- Immunological Assays

**Neglected Tropical Diseases Diagnosis Market Disease Type Outlook**

- Lymphatic Filariasis
- Schistosomiasis
- Leprosy
- Chagas Disease
- Dengue

**Neglected Tropical Diseases Diagnosis Market End User Outlook**

- Hospitals
- Diagnostic Laboratories
- Research Institutions
- Public Health Organizations

**Neglected Tropical Diseases Diagnosis Market Technology Outlook**

- PCR Technology
- Rapid Test Kits
- Next-Gen Sequencing
- Automated Analyzers

**Neglected Tropical Diseases Diagnosis Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa

## Market Drivers

### Government Initiatives and Funding

Government initiatives aimed at combating neglected tropical diseases significantly influence the Neglected Tropical Diseases Diagnosis Market. Various countries have launched programs to allocate funding for research and development of diagnostic tools. For instance, the United States Agency for International Development (USAID) has committed substantial resources to support NTD control programs. Such funding not only promotes innovation in diagnostic technologies but also encourages partnerships between public and private sectors. The financial backing from governments is likely to stimulate market growth, as it enables the development of more accurate and efficient diagnostic solutions, ultimately leading to better disease management and control.

### Increased Collaboration Among Stakeholders

Collaboration among various stakeholders, including governments, NGOs, and private companies, is a significant driver of the Neglected Tropical Diseases Diagnosis Market. Partnerships facilitate the sharing of resources, knowledge, and expertise, which is essential for developing effective diagnostic solutions. Initiatives such as the Global Fund and the Coalition for Operational Research on Neglected Tropical Diseases exemplify how collaborative efforts can lead to advancements in diagnostics. This synergy is likely to accelerate the development and distribution of innovative diagnostic tools, ultimately enhancing the capacity to diagnose and manage NTDs effectively.

### Technological Innovations in Diagnostic Tools

Technological advancements play a crucial role in shaping the Neglected Tropical Diseases Diagnosis Market. Innovations such as point-of-care testing, molecular diagnostics, and rapid test kits are transforming the landscape of NTD diagnostics. These technologies enhance the speed and accuracy of disease detection, which is vital for timely intervention. For example, the development of portable diagnostic devices allows for testing in remote areas where access to healthcare is limited. The market for these innovative diagnostic tools is projected to expand as healthcare providers seek efficient solutions to address the challenges posed by NTDs, thereby improving patient outcomes.

### Rising Incidence of Neglected Tropical Diseases

The increasing prevalence of neglected tropical diseases (NTDs) is a primary driver for the Neglected Tropical Diseases Diagnosis Market. According to the World Health Organization, over one billion people are affected by NTDs, which include diseases such as schistosomiasis, lymphatic filariasis, and leprosy. This rising incidence necessitates improved diagnostic tools and methods to facilitate early detection and treatment. As the burden of these diseases continues to grow, healthcare systems are compelled to invest in advanced diagnostic technologies. This trend is likely to enhance the market for NTD diagnostics, as stakeholders recognize the need for effective solutions to combat these diseases and improve public health outcomes.

### Growing Demand for Integrated Healthcare Solutions

The demand for integrated healthcare solutions is increasingly influencing the Neglected Tropical Diseases Diagnosis Market. As healthcare systems evolve, there is a shift towards comprehensive approaches that combine diagnostics, treatment, and prevention strategies. This trend is particularly relevant for NTDs, where early diagnosis is critical for effective management. Integrated solutions that encompass diagnostic testing alongside treatment protocols are gaining traction among healthcare providers. The market is expected to grow as stakeholders recognize the value of holistic approaches in addressing the complexities of NTDs, leading to improved health outcomes and resource allocation.

## Future Outlook

The Neglected Tropical Diseases Diagnosis Market is projected to grow at a 5.09% CAGR from 2025 to 2035, driven by technological advancements, increased funding, and rising awareness.

**New opportunities:**

- Development of rapid diagnostic kits for remote areas Integration of AI for predictive analytics in diagnostics Expansion of telemedicine platforms for remote consultations

By 2035, the market is expected to achieve substantial growth, enhancing global health outcomes.

## Segment Insights

### By Diagnostic Method: Serological Testing (Largest) vs. Molecular Diagnostics (Fastest-Growing)

In the Neglected Tropical Diseases Diagnosis Market, the diagnostic methods are categorized into serological testing, molecular diagnostics, microscopy, and immunological assays. Serological testing currently holds the largest market share due to its widespread applicability and reliable turnaround times. However, molecular diagnostics is gaining momentum, particularly in regions with a high prevalence of neglected tropical diseases, driven by the need for accurate and rapid results.

Serological Testing: Dominant vs. Molecular Diagnostics: Emerging

Serological testing is a dominant method in diagnosing neglected tropical diseases, valued for its ability to detect antibodies in patients. This method is widely used in resource-limited settings due to its relatively low cost and simplicity. On the other hand, molecular diagnostics represents an emerging segment, characterized by advanced technology that allows for the direct detection of pathogens' nucleic acids. This method is gaining traction due to its higher sensitivity and specificity, making it essential for timely identification and management of neglected tropical diseases.

### By Disease Type: Lymphatic Filariasis (Largest) vs. Schistosomiasis (Fastest-Growing)

In the Neglected Tropical Diseases Diagnosis Market, [Lymphatic Filariasis](https://www.marketresearchfuture.com/reports/lymphatic-filariasis-market-38927) holds the largest market share among the various disease types analyzed. This segment is widely prevalent in many regions, ensuring a significant allocation of healthcare resources and diagnostic efforts. In contrast, Schistosomiasis has emerged as the fastest-growing segment, experiencing a surge in both awareness and diagnostic capabilities, thanks to recent advancements in medical research and technology.

Lymphatic Filariasis (Dominant) vs. Schistosomiasis (Emerging)

Lymphatic Filariasis is recognized as a dominant force in the Neglected Tropical Diseases Diagnosis Market due to its extensive prevalence and substantial impact on public health. It primarily affects populations in tropical and subtropical regions, prompting ongoing efforts to enhance diagnostic methods and treatment options. On the other hand, Schistosomiasis is an emerging segment that has gained traction in recent years due to heightened awareness about its health implications. Its rapid growth is fueled by improvements in diagnostic technologies, increased funding for research, and a surge in public health initiatives aimed at disease eradication.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

The Neglected Tropical Diseases Diagnosis Market shows a diverse distribution among its end-user segments. Hospitals hold the largest share in this market, owing to their extensive resources and ability to provide immediate care for patients affected by neglected tropical diseases. Following closely, diagnostic laboratories are also significant contributors to this segment, as they play a crucial role in accurate and timely diagnoses, leading to better patient management. Research institutions and public health organizations, while equally important, represent smaller portions of the market due to their specialized focus on research and public health initiatives. In recent years, the market has seen a robust growth trend particularly driven by advancements in diagnostic technologies, increased funding for neglected diseases, and heightened awareness of health issues in underserved regions. Diagnostic laboratories are poised to exhibit the fastest growth due to their expanding capabilities and innovations in testing, which are essential for speedy disease identification and response. Conversely, hospitals continue to lead the field, benefiting from their integrated healthcare services and being primary treatment centers for these diseases.

Hospitals (Dominant) vs. Research Institutions (Emerging)

Hospitals are the dominant end users in the Neglected Tropical Diseases Diagnosis Market, largely due to their vast resources, comprehensive healthcare facilities, and their essential role in treating patients affected by these diseases. They benefit from a steady influx of patients requiring diagnosis and treatment, thereby positioning them as frontrunners in the market. In contrast, research institutions represent the emerging segment as they focus on innovative research and the development of new diagnostic techniques. Their contributions, while initially smaller, are crucial for future advancements in disease understanding and management. With increasing collaboration between hospitals and research institutions, the synergy between immediate clinical needs and long-term research goals is expected to propel efforts in combating neglected tropical diseases.

### By Technology: PCR Technology (Largest) vs. Rapid Test Kits (Fastest-Growing)

In the Neglected Tropical Diseases Diagnosis Market, PCR Technology represents the largest segment, capturing a significant portion of the overall market. This segment benefits from its accuracy and reliability in detecting various pathogens associated with neglected tropical diseases, making it a preferred choice among healthcare professionals. Conversely, Rapid Test Kits are experiencing remarkable growth, driven by the demand for quick and efficient diagnostic solutions. Their ability to deliver results in a short period enhances their appeal, especially in low-resource settings.

Technology: PCR Technology (Dominant) vs. Rapid Test Kits (Emerging)

PCR Technology is the dominant force in the Neglected Tropical Diseases Diagnosis Market, favored for its precision and the ability to detect low concentrations of pathogens. It is extensively used in laboratories for in-depth analysis and research, ensuring accurate diagnostics. In contrast, Rapid Test Kits are emerging as a disruptive innovation, providing a convenient alternative for immediate testing. These kits are easy to use, require minimal training, and are particularly beneficial in remote areas where laboratory access is limited. The growing focus on point-of-care testing is propelling the adoption of Rapid Test Kits in diagnosing neglected tropical diseases.

## Regional Market Share Analysis

### North America : Healthcare Innovation Leader

North America is the largest market for Neglected Tropical Diseases (NTDs) diagnosis, holding approximately 40% of the global market share. The region benefits from advanced healthcare infrastructure, significant investments in research and development, and a growing awareness of NTDs. Regulatory support from agencies like the FDA further catalyzes market growth, promoting innovative diagnostic solutions to combat these diseases. The United States and Canada are the leading countries in this region, with major players such as Abbott, Thermo Fisher Scientific, and BD driving competition. The presence of established healthcare systems and a focus on technological advancements in diagnostics contribute to a robust competitive landscape. These companies are actively engaged in partnerships and collaborations to enhance their product offerings and expand market reach.

### Europe : Regulatory Framework Enhancements

Europe is the second-largest market for NTD diagnosis, accounting for approximately 30% of the global market share. The region is witnessing increased demand for innovative diagnostic tools driven by rising awareness of neglected tropical diseases and supportive regulatory frameworks. The European Medicines Agency (EMA) is actively involved in streamlining approval processes for new diagnostic technologies, which is expected to further boost market growth. Leading countries in Europe include Germany, France, and the UK, where key players like Siemens Healthineers and Roche are prominent. The competitive landscape is characterized by a mix of established companies and emerging startups focusing on niche diagnostic solutions. Collaborative efforts between public health organizations and private entities are enhancing the availability of effective diagnostic tools across the region.

### Asia-Pacific : Emerging Market Potential

Asia-Pacific is an emerging powerhouse in the NTD diagnosis market, holding about 20% of the global market share. The region is experiencing rapid growth due to increasing healthcare investments, rising disease prevalence, and government initiatives aimed at improving healthcare access. Countries like India and China are focusing on enhancing their diagnostic capabilities, supported by favorable regulatory environments that encourage innovation in healthcare technologies. India and China are the leading countries in this region, with a growing number of local and international players entering the market. Companies like Hologic and Bio-Rad Laboratories are expanding their presence, driven by partnerships with local healthcare providers. The competitive landscape is evolving, with a focus on affordable and accessible diagnostic solutions tailored to the needs of diverse populations.

### Middle East and Africa : Resource-Rich Frontier

The Middle East and Africa (MEA) region represents a unique market for NTD diagnosis, holding approximately 10% of the global market share. The region faces significant challenges, including limited healthcare infrastructure and varying levels of disease awareness. However, there is a growing recognition of the need for improved diagnostic solutions, driven by international health organizations and local governments aiming to combat NTDs effectively. Leading countries in the MEA region include South Africa and Nigeria, where efforts are being made to enhance diagnostic capabilities. The competitive landscape is characterized by a mix of multinational corporations and local firms. Companies like Cepheid are actively working to introduce innovative diagnostic tools tailored to the region's specific needs, fostering collaboration with local health authorities to improve disease management.

## Competitive Benchmarking

The Neglected Tropical Diseases Diagnosis Market is characterized by a complex interplay of competitive dynamics, driven by the urgent need for effective diagnostic solutions in regions heavily impacted by these diseases. Key players such as Roche (CH), Abbott (US), and Siemens Healthineers (DE) are at the forefront, each adopting distinct strategies to enhance their market presence. Roche (CH) emphasizes innovation through the development of advanced diagnostic technologies, while Abbott (US) focuses on expanding its product portfolio to include rapid testing solutions. Siemens Healthineers (DE) is strategically positioned through partnerships aimed at enhancing diagnostic capabilities in underserved markets. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological advancement and accessibility. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to better serve emerging markets. The market structure appears moderately fragmented, with several players vying for dominance. However, the influence of major companies is significant, as they leverage their resources to establish a foothold in regions where neglected tropical diseases are prevalent. This competitive landscape is shaped by the need for rapid and reliable diagnostics, which is critical for effective disease management. In August 2025, Roche (CH) announced the launch of a new point-of-care diagnostic test specifically designed for the detection of schistosomiasis, a prevalent neglected tropical disease. This strategic move not only enhances Roche's product offerings but also addresses a critical gap in rapid diagnostics for this disease, potentially improving patient outcomes in affected regions. The introduction of such innovative solutions underscores Roche's commitment to addressing global health challenges through advanced technology. In September 2025, Abbott (US) expanded its collaboration with local health authorities in sub-Saharan Africa to enhance the distribution of its rapid diagnostic tests for various neglected tropical diseases. This initiative reflects Abbott's strategy to localize its operations and ensure that its products are accessible to populations in need. By strengthening partnerships with regional health systems, Abbott is likely to improve its market penetration and foster trust within local communities. In July 2025, Siemens Healthineers (DE) entered into a strategic alliance with a non-governmental organization focused on improving healthcare infrastructure in rural areas of Southeast Asia. This partnership aims to facilitate the deployment of advanced diagnostic technologies in regions severely affected by neglected tropical diseases. Such collaborations not only enhance Siemens Healthineers' market reach but also align with global health initiatives aimed at eradicating these diseases. As of October 2025, the competitive trends in the Neglected Tropical Diseases Diagnosis Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in diagnostic processes. Strategic alliances are becoming pivotal in shaping the landscape, as companies seek to combine resources and expertise to tackle complex health challenges. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and the reliability of supply chains, which will be essential for meeting the growing demand for effective diagnostic solutions.

## Recent News & Developments

Recent developments in the Neglected Tropical Diseases Diagnosis Market have drawn significant attention, particularly concerning advancements in diagnostic technologies and innovative partnerships. Companies like Siemens Healthineers and Thermo Fisher Scientific have implemented novel diagnostic solutions that enhance the detection of neglected tropical diseases (NTDs). Merck has been focusing on research collaborations aimed at accelerating the development of diagnostic tools for diseases such as schistosomiasis and lymphatic filariasis.

Notably, Becton Dickinson has seen increased demand for NTD diagnostic kits, contributing to a notable growth in its market valuation, reflecting the rising global awareness of these diseases. On the merger and acquisition front, significant movements have been observed, including Roche's acquisition of a biotech company specializing in infectious diseases, which aims to strengthen its portfolio in the NTD diagnostics sector. Additionally, Abbott and Cepheid are reported to be expanding their product lines to include rapid tests for various NTDs, which could reshape market dynamics.

The combined efforts of these companies are contributing to the overall growth and improving response strategies to combat neglected tropical diseases effectively.

## Report Scope

| MARKET SIZE 2024 | 8.751(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 9.197(USD Billion) |
| MARKET SIZE 2035 | 15.11(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.09% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), Abbott (US), Siemens Healthineers (DE), Thermo Fisher Scientific (US), BD (US), Cepheid (US), Hologic (US), Bio-Rad Laboratories (US) |
| Segments Covered | Diagnostic Method, Disease Type, End User, Technology, Regional |
| Key Market Opportunities | Advancements in rapid diagnostic technologies enhance detection capabilities in the Neglected Tropical Diseases Diagnosis Market. |
| Key Market Dynamics | Technological advancements in diagnostics enhance detection capabilities for neglected tropical diseases, driving market growth and innovation. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Neglected Tropical Diseases Diagnosis Market by 2035?**
A: The projected market valuation for the Neglected Tropical Diseases Diagnosis Market is expected to reach 15.11 USD Billion by 2035.

**Q: What was the market valuation of the Neglected Tropical Diseases Diagnosis Market in 2024?**
A: The overall market valuation was 8.751 USD Billion in 2024.

**Q: What is the expected CAGR for the Neglected Tropical Diseases Diagnosis Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Neglected Tropical Diseases Diagnosis Market during the forecast period 2025 - 2035 is 5.09%.

**Q: Which diagnostic method segment is projected to grow the most by 2035?**
A: The Immunological Assays segment, valued at 4.25 USD Billion in 2024, is projected to grow to 7.35 USD Billion by 2035.

**Q: What are the key players in the Neglected Tropical Diseases Diagnosis Market?**
A: Key players in the market include Roche, Abbott, Siemens Healthineers, Thermo Fisher Scientific, BD, Cepheid, Hologic, and Bio-Rad Laboratories.

**Q: Which disease type segment is expected to see the highest growth by 2035?**
A: The Dengue segment, valued at 4.251 USD Billion in 2024, is expected to grow to 7.51 USD Billion by 2035.

**Q: What is the projected growth for the Molecular Diagnostics segment by 2035?**
A: The Molecular Diagnostics segment is projected to grow from 2.0 USD Billion in 2024 to 3.5 USD Billion by 2035.

**Q: How does the market for diagnostic laboratories compare to hospitals in 2025?**
A: In 2024, the market for diagnostic laboratories was valued at 2.1 USD Billion, while hospitals were valued at 2.625 USD Billion, indicating a competitive landscape.

**Q: What technology segment is anticipated to have the highest valuation by 2035?**
A: The Rapid Test Kits segment, valued at 3.0 USD Billion in 2024, is anticipated to reach 5.0 USD Billion by 2035.

**Q: What role do public health organizations play in the Neglected Tropical Diseases Diagnosis Market?**
A: Public health organizations are projected to increase their market share from 2.526 USD Billion in 2024 to 4.61 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/neglected-tropical-diseases-diagnosis-market-34022*